Vittorio CC - Search Results

1

Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.

Stephen S, Morrissey KA, Benoit BM, Kim EJ, Vittorio CC, Nasta SD, Showe LC, Wysocka M, Rook AH. Stephen S, et al. Among authors: vittorio cc. Am J Hematol. 2012 Feb;87(2):226-8. doi: 10.1002/ajh.22231. Epub 2011 Dec 21. Am J Hematol. 2012. PMID: 22189940 Free PMC article.

2

Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH. Kim EJ, et al. Among authors: vittorio cc. J Clin Invest. 2005 Apr;115(4):798-812. doi: 10.1172/JCI24826. J Clin Invest. 2005. PMID: 15841167 Free PMC article. Review.

3

A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.

Gardner JM, Introcaso CE, Nasta SD, Kim EJ, Vittorio CC, Rook AH. Gardner JM, et al. Among authors: vittorio cc. J Am Acad Dermatol. 2009 Jul;61(1):112-6. doi: 10.1016/j.jaad.2008.11.889. J Am Acad Dermatol. 2009. PMID: 19539845

4

Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.

Gardner JM, Evans KG, Goldstein S, Kim EJ, Vittorio CC, Rook AH. Gardner JM, et al. Among authors: vittorio cc. Arch Dermatol. 2009 Sep;145(9):985-8. doi: 10.1001/archdermatol.2009.229. Arch Dermatol. 2009. PMID: 19770436 No abstract available.

5

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.

Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH. Cedeno-Laurent F, et al. Among authors: vittorio cc. Clin Immunol. 2015 May;158(1):1-7. doi: 10.1016/j.clim.2015.02.014. Epub 2015 Mar 8. Clin Immunol. 2015. PMID: 25762519 Free PMC article.

6

Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma.

Samimi S, Morrissey K, Anshelevich S, Evans K, Gardner J, Musiek A, Vittorio C, Rook A, Kim E. Samimi S, et al. J Am Acad Dermatol. 2013 Jan;68(1):e5-6. doi: 10.1016/j.jaad.2011.06.043. J Am Acad Dermatol. 2013. PMID: 23244387 No abstract available.

7

Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab.

Mollanazar NK, Savage KT, Pousti BT, Jariwala N, Del Guzzo C, Haun P, Vittorio C, Rook AH, Kim EJ. Mollanazar NK, et al. Cutis. 2020 Sep;106(3):131-132. doi: 10.12788/cutis.0066. Cutis. 2020. PMID: 33104116

8

New biologic agents for the treatment of cutaneous T-cell lymphoma.

Vittorio CC, Junkins-Hopkins JM, McGinnis KS, Shapiro M, Wysocka M, Zaki MH, French LE, Rook AH. Vittorio CC, et al. Recent Results Cancer Res. 2002;160:321-8. doi: 10.1007/978-3-642-59410-6_37. Recent Results Cancer Res. 2002. PMID: 12079230 Review.

9

Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.

Rook AH, Junkins-Hopkins JM, McGinnis KS, Wysocka M, Richardson SK, Budgin JB, Everitts S, Vittorio CC. Rook AH, et al. Among authors: vittorio cc. Adv Dermatol. 2002;18:29-43. Adv Dermatol. 2002. PMID: 12528401 Review.

10

Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.

McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM. McGinnis KS, et al. Among authors: vittorio cc. Arch Dermatol. 2003 Jun;139(6):771-5. doi: 10.1001/archderm.139.6.771. Arch Dermatol. 2003. PMID: 12810509 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters